<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391884</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2009-158-UREMINC</org_study_id>
    <nct_id>NCT01391884</nct_id>
  </id_info>
  <brief_title>Elimination of Incretin Hormones in Patients With Severe Kidney Failure</brief_title>
  <official_title>Elimination and Biodegradation of the Incretin Hormones GLP-1 and GIP in Patients With End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bo Feldt-Rasmussen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of type 2 diabetes (T2D) is increasing rapidly worldwide. T2D is characterized&#xD;
      by a severely impaired incretin effect. The incretin effect refers to the insulinotropic&#xD;
      action of the nutrient-released incretin hormones glucagon-like peptide-1 (GLP-1) and&#xD;
      glucose-dependent insulinotropic peptide (GIP). The incretin effect is defined as the&#xD;
      difference in insulin secretory responses between oral and isoglycaemic intravenous glucose&#xD;
      challenges (OGTT and IIGI, respectively) and in healthy individuals it accounts for as much&#xD;
      as 70% of the insulin response following oral glucose, whereas patients with T2D exhibit an&#xD;
      incretin effect in the range of 0 to 30%. Patients with T2D and non-diabetic patients with&#xD;
      severe kidney failure share several pathophysiological characteristics, including decreased&#xD;
      insulin sensitivity, fasting hyperinsulinaemia and impaired beta-cell function. The reason&#xD;
      for these findings remains to be fully elucidated. An ongoing study in our research group is&#xD;
      investigating the incretin effect and the incretin hormone secretory responses following&#xD;
      OGTT, IIGI and meal ingestion, respectively. In continuation of this study, essential&#xD;
      knowledge of metabolism of incretin hormones in an uremic milieu will be obtained in the&#xD;
      present study prior to evaluation of the use of incretin-based agents in patients with&#xD;
      impaired kidney function. In this second study we evaluate the elimination and biodegradation&#xD;
      of GLP-1 and GIP. The biological active incretin hormones are rapidly degraded by the&#xD;
      ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4), generating inactive metabolites. The active&#xD;
      hormones are however also eliminated by renal clearance, although the importance of this&#xD;
      remains questionable. It is likely that the degradation and elimination of the active&#xD;
      hormones will be significantly affected in patients with severe kidney impairment.&#xD;
&#xD;
      We hypothesize that elimination and biodegradation of the two incretin hormones, both in itÂ´s&#xD;
      active and inactive forms, will be affected in non-diabetic patients with severe kidney&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intact GLP-1 concentration</measure>
    <time_frame>-60 min - 180 min</time_frame>
    <description>During GLP-1 infusion 0-60 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total GLP-1 concentration</measure>
    <time_frame>-60 min - 180 min</time_frame>
    <description>GLP-1 infusion 0-60 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intact GIP concentration</measure>
    <time_frame>- 60 min - 180 min</time_frame>
    <description>GIP infusion 0-60 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total GIP infusion</measure>
    <time_frame>-60 min - 180 min</time_frame>
    <description>GIP infusion 0-60 min</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Uremia</condition>
  <arm_group>
    <arm_group_label>Dialysis, Non-diabetic</arm_group_label>
    <description>Hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Hemodialysis patients&#xD;
&#xD;
          2. Healthy control subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female; aged 18-90 years&#xD;
&#xD;
          -  CKD stage 5 in chronic maintenance dialysis treatment&#xD;
&#xD;
          -  BMI: 18,5-28 kg/m2&#xD;
&#xD;
          -  Normal fasting plasma glucose (&lt;6,1 mM)&#xD;
&#xD;
          -  Normal or impaired glucose tolerance (PG120 min &lt;11,1 mM following OGTT)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female; aged 18-90 years&#xD;
&#xD;
          -  Healthy including normal kidney function&#xD;
&#xD;
          -  BMI: 18,5-28 kg/m2&#xD;
&#xD;
          -  Normal fasting plasma glucose (&lt;6,1 mM)&#xD;
&#xD;
          -  Normal or impaired glucose tolerance (PG120 min &lt;11,1 mM following OGTT)&#xD;
&#xD;
        1+2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Chronic pancreatitis / previous acute pancreatitis&#xD;
&#xD;
          -  Treatment with oral glucocorticoids, calcineurin inhibitors, thiazides, dipeptidyl&#xD;
             peptidase 4 (DPP4) inhibitors or other drugs, which could interfere with glucose or&#xD;
             lipid metabolism&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Malignant disease&#xD;
&#xD;
          -  Bowel resection&#xD;
&#xD;
          -  Severe anemia (hemoglobin &lt;6.5 mmol/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Bo Feldt-Rasmussen</investigator_full_name>
    <investigator_title>MD DMSc</investigator_title>
  </responsible_party>
  <keyword>Incretin hormones</keyword>
  <keyword>GLP-1</keyword>
  <keyword>GIP</keyword>
  <keyword>Uremia</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

